TY  - JOUR 
AU  - Albanell, J.
AU  - Pérez-García, J.M.
AU  - Gil-Gil, M.
AU  - Curigliano, G.
AU  - Ruíz-Borrego, M.
AU  - Comerma, L.
AU  - Gibert, J.
AU  - Bellet, M.
AU  - Bermejo, B.
AU  - Calvo Martínez, Lourdes
AU  - de la Haba, J.
AU  - Espinosa, E.
AU  - Minisini, A.M.
AU  - Quiroga, V.
AU  - Santaballa Bertran, A.
AU  - Mina, L.
AU  - Bellosillo, B.
AU  - Rojo, F.
AU  - Menéndez, S.
AU  - Sampayo-Cordero, M.
AU  - Popa, C.
AU  - Malfettone, A.
AU  - Cortés, J.
AU  - Llombart-Cussac, A.
PY  - 2023
SN  - 1557-3265
UR  - http://hdl.handle.net/20.500.11940/21826
AB  - PURPOSE: To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond progression on prior palbociclib-based regimen in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast...
LA  - eng
KW  - Female
KW  - Humans
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Piperazines
TI  - Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
DO  - 10.1158/1078-0432.ccr-22-1281
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
M2  - 67
KW  - AS A Coruña
KW  - CHUAC
VL  - 29
ER  -